ARM and NIIMBL Release Project A-Cell to Bring Quality by Design Principles to Cell-Based Therapy Manufacturing
July 26, 2022
The Alliance for Regenerative Medicine (ARM) and the National Institute for Innovation in Manufacturing BioPharmaceuticals (NIIMBL) today released Project A-Cell, a multistakeholder collaboration to incorporate Quality by Design (QbD) principles into a manufacturing case study of a Chimeric Antigen Receptor T-cell (CAR-T) therapy.
Alliance for Regenerative Medicine Announces CEO Transition
April 27, 2022
Janet Lynch Lambert will step down as the CEO of the Alliance for Regenerative Medicine after guiding the leading international advocacy organization for cell, gene and tissue-engineered therapies through five years of extraordinary growth in membership, funding, and influence.
Cell and Gene Therapies Poised to Disrupt Health Care Status Quo with Wave of New Treatments
March 31, 2022
The Alliance for Regenerative Medicine, the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today released its 2021 Annual Report, showcasing a year of significant advances and forecasting continued growth ahead.